0845 GMT - Sanofi's deal to buy U.K. biotech company Vicebio for up to $1.6 billion should strengthen its vaccine portfolio and could make up for pipeline setbacks, AlphaValue says. If Vicebio's candidates clear clinical and regulatory hurdles to reach the market, this could help Sanofi offset the research-and-development setbacks it suffered in recent years, the equity-research firm says in a market comment. Moreover, Vicebio's vaccine technology, called molecular clamp, enables vaccines to be stored at standard refrigeration temperature, which eliminates the need for freezing them and facilitates manufacturing and distribution, AlphaValue says. Sanofi shares trade 0.1% higher. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

July 22, 2025 04:45 ET (08:45 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.